1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search results consecutively by pressing the navigational buttons
(
<
1 of
6
>).
Within the text the search result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
The operating activities of the Merck Group are organized into four divisions. The Merck Serono division develops, manufactures and markets prescription drugs to treat cardiovascular diseases, cancer, neurodegenerative diseases, infertility treatment and selected metabolic disorders. More than 60% of Merck Serono’s sales are generated with biologics, making the division one of Europe’s leading suppliers of biopharmaceuticals. In the second quarter of 2013, Merck Serono accounted for around 56% of Group sales. The Consumer Health division manufactures and markets over-the-counter pharmaceuticals that primarily address health themes such as mobility, women’s [...]
[...] year. In a first step, the allocation of expenses for Group functions of Merck KGaA to the operating divisions was modified in fiscal 2012. In a further step, the corresponding disclosures for the consolidated subsidiaries were adjusted in fiscal 2013. Consequently, expenses for Group functions are no longer allocated to the operating divisions, but rather disclosed fully in the column “Corporate and Other” in the Segment Reporting. In order to ensure comparability, the previous year’s Segment Reporting figures have been adjusted in accordance with the allocation rules for 2013. The notes to the consolidated financial statements of the Merck Group for 2012, [...]
Highlights – 2nd Quarter 2013 Organic sales growth of 3.3% despite more difficult markets Positive effects of efficiency program “Fit for 2018” well on track Margin expansion in nearly all divisions Increase in EBITDA pre one-time items of 10.7% to € 826 million EPS pre one-time items lifted by 17.7% to € 2.26 Continuous net financial debt reduction to € 1.3 billion at the end of the quarter Guidance for 2013 confirmed despite adverse currency effects: EBITDA pre one-time items ~€ 3.1 to € 3.2 billion XLS Merck Group | Key figures € million Q2 – 2013 Q2 – 2012 Change Jan.–June 2013 Jan.–June 2012 Change Total revenues 2,841.1 2,852.1 [...]
Highlights – 2nd Quarter 2013 Organic sales growth of 3.3% despite more difficult markets Positive effects of efficiency program “Fit for 2018” well on track Margin expansion in nearly all divisions Increase in EBITDA pre one-time items of 10.7% to € 826 million EPS pre one-time items lifted by 17.7% to € 2.26 Continuous net financial debt reduction to € 1.3 billion at the end of the quarter Guidance for 2013 confirmed despite adverse currency effects: EBITDA pre one-time items ~€ 3.1 to € 3.2 billion XLS Merck Group | Key figures € million Q2 – 2013 Q2 – 2012 Change Jan.–June 2013 Jan.–June 2012 Change Total revenues 2,841.1 2,852.1 [...]
Corporate and Other comprises Group administration expenses for Group functions that cannot be directly allocated to the divisions. This includes Group functions such as Finance, Procurement, Legal, Communications, and Human Resources. Corporate costs also include expenses for central, non-allocated IT functions, also related to the expansion and harmonization of IT systems within the Merck Group. As a result, Corporate and Other has no sales to report. Gains or losses on currency hedging are also reported in Corporate and Other. XLS Corporate and Other | Key figures € million Q2 – 2013 Q2 – 2012 Change Jan.–June 2013 Jan.–June 2012 Change Total revenues [...]
